ArticlePlant biotechnology journal2026
A Lambda Red Recombinase-Assisted CRISPR/Cas9 System for Efficient and Precise Genome Editing in Agrobacterium tumefaciens.
Article in Plant biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Agrobacterium tumefaciens is a powerful delivery tool for plant genetic transformation and a pivotal platform for agricultural biotechnology. However, laboratory strains of Agrobacterium have remained genetically unoptimized for decades, with genome engineering hindered by inefficient, endogenous homologous recombination systems. Here, we developed and optimized a lambda (λ) Red recombinase-assisted CRISPR/Cas9 system that enables efficient and precise introduction of point mutations, insertions, deletions and large fragment replacements into both the chromosome and Ti plasmids of different A. tumefaciens strains, with minimal off-target editing. Editing efficiencies across eighteen target sites ranged from 26.7% to 100%, demonstrating the versatility of this method. Furthermore, we incorporated a SacB counter-selection marker into our system that facilitates the plasmids curing after editing. Using this platform, we sequentially deleted four antibiotic-resistance loci in strain EHA105, generating an antibiotic-sensitive derivative, EHA105-S, that maintains wild-type growth kinetics and transformation efficiency. Additionally, we engineered the microbe-associated molecular pattern (MAMPs) of two elongation factor Tu (EF-Tu) genes, allowing the A. tumefaciens to escape EF-Tu receptor (EFR) perception. The resulting engineered strains displayed enhanced transient expression efficiency in Arabidopsis thaliana. Our λ Red-assisted CRISPR/Cas9 system thus provides a robust, scalable and user-friendly tool for Agrobacterium genome engineering, paving the way for the design of next-generation strains to revolutionize plant transformation and advance synthetic biology applications in plants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.